Meeting
2014 ASCO Annual Meeting
A phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone (QUAD) in relapsed and/or refractory multiple myeloma (MM).
Authors
David H. Vesole
John Theurer Cancer Center, Hackensack, NJ
David H. Vesole , David Samuel DiCapua Siegel , Joshua Ryan Richter , Ann McNeill , Palka Anand , Urszula Bednarz , Kristin Ivanovski , Laura McBride , Laura Raucci , Veena Batra , Adolfo Aleman , Taliah Sims , Laura Guerrero , Judith Smith , Anthony R. Mato , Elizabeth Bilotti
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Highlights Session
Session Title
Lymphoma and Plasma Cell Disorders
Track
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sub Track
Multiple Myeloma
Clinical Trial Registration Number
NCT01297764
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 8535^)
DOI
10.1200/jco.2014.32.15_suppl.8535
Abstract #
8535^
Poster Bd #
15
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Phase 1 study of tasquinimod, an S100A9 inhibitor, alone and in combination with IRd for relapsed and refractory multiple myeloma (RRMM).
First Author: Dan T. Vogl
Poster
2021 ASCO Annual Meeting
Once weekly selinexor, carfilzomib, and dexamethasone (XKd) in carfilzomib nonrefractory multiple myeloma (MM) patients.
First Author: Cristina Gasparetto
Poster
2018 ASCO Annual Meeting
A phase II study of elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma.
First Author: Andrew Jenho Yee
Poster
2016 ASCO Annual Meeting
Adverse event (AE) management in patients (pts) with relapsed and refractory multiple myeloma (RRMM) taking pomalidomide (POM) plus low dose-dexamethasone (LoDEX): A pooled analysis from 3 clinical trials.
First Author: Philippe Moreau